Monopar Therapeutics Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. Monopar is a clinical-stage biopharmaceutical company with no approved products and no revenue from operations.
Business context and pipeline
- Validive: Phase 2b/3 VOICE trial for prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer. The first patient was dosed in February 2021; an interim analysis was expected in Q1 2022, with progression to Phase 3 dependent on the results.
- Camsirubicin: Phase 2 candidate for advanced soft tissue sarcoma. A GEIS-led randomized trial against doxorubicin was expected to begin in Q2 2021 and enroll approximately 170 patients.
- MNPR-101: Preclinical uPAR-targeted antibody program for cancer, with exploratory COVID-19 therapeutic, diagnostic, and imaging applications.
Financial and liquidity highlights
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue from operations | None | None |
| Research and development expense | $4.065 million | $1.969 million |
| General and administrative expense | $2.444 million | $2.355 million |
| Total operating expenses / operating loss | $6.509 million | $4.324 million |
| Net loss | $6.305 million | $4.225 million |
| Basic and diluted net loss per share | $0.58 | $0.45 |
| Net cash used in operating activities | $4.662 million | $3.018 million |
| Net cash provided by financing activities | $8.182 million | $9.347 million |
| Cash and cash equivalents at year-end | $16.737 million | $13.214 million |
| Total current liabilities | $1.177 million | $0.724 million |
| Total liabilities | $1.177 million | $0.724 million |
Margins are not meaningful because the company had no operating revenue. The filing reports no material debt outstanding at year-end; a $122,400 Paycheck Protection Program loan was forgiven in December 2020 and recorded as other income. Current assets were $16.800 million at year-end, compared with current liabilities of $1.177 million.
Management attributed the $2.096 million increase in R&D expense mainly to camsirubicin trial planning and manufacturing, personnel costs, and increased clinical activity. Net loss widened by $2.080 million. Cash used in operations increased by $1.644 million, while financing cash inflows were lower than in 2019, when the IPO contributed proceeds.
Outlook, risks, and other notable items
- Management estimated that available funds as of March 5, 2021 would fund planned operations through at least March 2022. The filing says completing the VOICE program could require additional funding in the millions or tens of millions of dollars, depending on any partnership. That estimate is forward-looking and subject to change.
- From January 1 through February 11, 2021, Monopar sold 1,104,047 shares under its at-the-market sales agreement for net proceeds of approximately $10.9 million. This subsequent financing supports liquidity but increases share count and may dilute existing holders.
- GEIS-related and other camsirubicin clinical expenses were $1.4 million in 2020, versus $0.2 million in 2019. The company expected to contribute approximately $2 million to $3 million per year to the GEIS trial.
- Material risks include continued losses and reliance on external financing; clinical, regulatory, enrollment, and manufacturing uncertainty; COVID-19-related disruption; reliance on third parties; competition; intellectual-property and licensing risks; and potential equity dilution. Failure to secure funding or a suitable partner could delay, reduce, out-license, or terminate programs.
- No material legal proceedings were reported. Management assessed internal control over financial reporting and disclosure controls as effective at December 31, 2020. The independent auditor gave an unqualified opinion on the financial statements and was not engaged to audit internal control.
Most important facts for investors to verify
- Current cash, cash burn, and runway against the filing’s March 2022 estimate, including subsequent financing and spending.
- VOICE enrollment, interim-analysis timing and outcome, FDA alignment on the trial design, and the funding needed to complete the program.
- GEIS trial start, run-in findings, enrollment progress, and Monopar’s ongoing financial commitments.
- MNPR-101 development milestones and whether its proposed cancer and COVID-19 applications advance beyond preclinical or exploratory work.
- Potential dilution from future financings, options, and restricted stock units, and the effect of significant stockholder voting control.